OBJECTIVES: To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HIV-1 vaccine using an inactivated but immunogenic Tat (Tat toxoid). Tat toxoid has been assayed for safety and immunogenicity in seropositive patients. METHOD: The phase I vaccine clinical trial testing Tat toxoid preparation in Seppic Isa 51 oil adjuvant was performed on 14 HIV-1-infected asymptomatic although biologically immunocompromised individuals (500-200 CD4+ cells/mm3). RESULTS: Following as many as 8 injections, no clinical defects were observed. All patients exhibited an antibody (Ab) response to Tat, and some had cell-mediated immunity (CMI) as evaluated by skin test in vivo and T-cell proliferation in vitro. CONCLUSION: These results provide initial evidence of safety and potency of Tat toxoid vaccination in HIV-1-infected individuals
Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients / A. Gringeri, E. Santagostino, M. Perja, P. M. Mannucci, J. F. Zagury, B. Bizzini, A. Lachgar, M. Carcagno, J. Rappaport, M. Criscuolo, W. Blattner, A. Burny, R. C. Gallo, D. Zagury. - In: JOURNAL OF HUMAN VIROLOGY. - ISSN 1090-9508. - 1:4(1998), pp. 293-298.
|Titolo:||Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients|
GRINGERI, ALESSANDRO (Primo)
|Parole Chiave:||HIV-1 ; vaccine ; Tat toxoid|
|Settore Scientifico Disciplinare:||Settore MED/09 - Medicina Interna|
|Data di pubblicazione:||1998|
|Appare nelle tipologie:||01 - Articolo su periodico|